Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?

Erlend Skaga, Marthe Andrea Skretteberg, Tom Børge Johannesen, Petter Brandal, Einar O. Vik-Mo, Eirik Helseth, and Iver A. Langmoen

Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research and Department of Neurosurgery, Oslo University Hospital, Oslo, Norway (E.S., E.O.V.M., E.H., I.A.L.); Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway (M.A.S., E.H., I.A.L.); Department of Registration, Cancer Registry of Norway, Oslo, Norway (T.B.J.); Department of Oncology, Oslo University Hospital, Oslo, Norway (P.B.)

Corresponding Author: Erlend Skaga, MD, PhD, Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research and Department of Neurosurgery, Oslo University Hospital, PO.Box 4950, Nydalen, 0424 Oslo, Norway (erlend.skaga@gmail.com).

Abstract

Background. The survival rates in population-based series of glioblastoma (GBM) differ substantially from those reported in clinical trials. This discrepancy may be attributed to that patients recruited to trials tend to be younger with better performance status. However, the proportion and characteristics of the patients in a population considered either eligible or ineligible for trials is unknown. The generalizability of trial results is therefore also uncertain.

Methods. Using the Cancer Registry of Norway and the Brain Tumor Database at Oslo University Hospital, we tracked all patients within a well-defined geographical area with newly diagnosed GBM during the years 2012–2017. Based on data from these registries and the medical records, the patients were evaluated for trial eligibility according to criteria employed in recent phase III trials for GBM.

Results. We identified 512 patients. The median survival was 11.7 months. When we selected a potential trial population at the start of concurrent chemoradiotherapy (radiotherapy [RT] / temozolomide [TMZ]) by the parameters age (18–70 y), passed surgery for a supratentorial GBM, Eastern Cooperative Oncology Group (ECOG) ≤2, normal hematologic, hepatic and renal function, and lack of severe comorbidity, 57% of the patients were excluded. Further filtering the patients who progressed during RT/TMZ and never completed RT/TMZ resulted in exclusion of 59% and 63% of the patients, respectively. The survival of patients potentially eligible for trials was significantly higher than of the patients not fulfilling trial eligibility criteria (P < .0001).

Conclusions. Patients considered eligible for phase III clinical trials represent a highly selected minority of patients in a real-world GBM population.

Key Points

1. A minority of GBM patients are eligible for clinical trials.
2. Patients in trials are not representative for a real-world GBM population.
3. The extrapolation of trial results to the real-world population is uncertain.

The median survival of patients with newly diagnosed glioblastoma (GBM), the most frequent and most malignant primary brain tumor, is commonly claimed to be about 15 months. Although valid for the subgroup of patients who are entered into randomized clinical trials (RCT) and typically undergo multimodal treatment with surgery, radiotherapy
Importance of the Study

Clinical trials are fundamental for therapeutic advances in GBM and according to the National Comprehensive Cancer Network, the best management of a cancer patient is in a trial. However, by current trial inclusion and exclusion criteria, only a selected group of patients can be considered eligible for trials. This bias not only restricts patients from receiving the best care, but also makes it difficult to extrapolate trial results to a real-world population. Here, we estimated the proportion of GBM patients who did not fulfill eligibility criteria for trial participation and compared the characteristics of patients considered trial participants to those excluded. We found that approximately 60% of patients were ineligible for trials. These patients were older, had worse performance status, received less treatment and had worse survival. This implies that the current trial landscape inadequately reflects the population, and that generalizability of trials results into clinical practice carries considerable uncertainty.

Materials and Methods

Population Base

Each person in Norway is registered in The National Population Register with a unique ID number and contact information that facilitates contact between health care officials and individual patients. In this study, we collected data from the counties Akershus, Buskerud, Oslo, Telemark, Vestfold, and Østfold since all patients from these counties receive their oncological treatment at Oslo University Hospital (OUH). This defined geographical area comprised 2.2 million people (43.9% of the Norwegian population) during the study period.

Cancer Registries

To identify the patients in this study, we used the Cancer Registry of Norway (CRN) and the Brain Tumor Database (BTD) at Oslo University Hospital.

The CRN was founded in 1951, and it maintains a prospective database of all tumors diagnosed in Norway, including both malignant and benign tumors of the central nervous system (CNS). Reporting to the registry is compulsory by law, and the registry is based on clinicians’ reports, pathology reports, and information from death certificates reporting neoplastic disease. The quality of the registry is maintained by ensuring that missing reports from attending clinicians or pathologists are requested by direct contact. Data from the CRN have undergone quality control and are valid for population studies. The tumors from the time period in this study were coded according to the third revision of the International Classification of Diseases for Oncology (ICD-O-3, primary GBM, site codes 710–719, and histology codes 9440–9442). The registry also retrieves data electronically, ensuring information on oncological treatment (RT and TMZ) in all patients. The unique identification number of each individual is maintained by the government and change to death status is conveyed to the CRN. This study has used data from the CRN. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the CRN is intended nor should be inferred.

The BTD is a prospective database containing details of all tumor resections and biopsies carried out in the Department of Neurosurgery, OUH. The registry retrieves...
data electronically from every patient, including name, unique ID number, sex, age at diagnosis, tumor localization, type of surgical treatment, pathology, and survival.

**Patient Data**

Using the BTD we identified all patients diagnosed with GBM (n = 512) between 2012 and 2017 from the defined counties. By using the CRN, we could also identify the patients who were diagnosed by MRI only. Two of the authors independently undertook a systematic review of the medical records of the individual patients in order to obtain the required data which included the following: sex, age at diagnosis, tumor localization (dichotomized into supra- or infratentorial), performance status by the Eastern Cooperative Oncology Group (ECOG) evaluated preoperatively, as well as before the start, at midway and at the end of concurrent RT/TMZ, type of primary surgery (no surgery, stereotactic biopsy, open biopsy or resection), primary oncological treatment (RT and TMZ), other comorbidities (heart, hepatic, immunologic, lung, psychiatric, or renal disease, coagulation insufficiency, previous malignancy, previous oncological treatment, and other disorders of the CNS, eg, dementia), medication use before the diagnosis of GBM (number of drugs taken daily that required prescription from a physician), the use and doses of steroids before, midway and at the end of concurrent RT/TMZ, disease status (progressive or not progressive disease) until finished radiochemotherapy phase, and blood levels of white blood cells (WBC), thrombocytes (Tbc), creatinine, bilirubin, aspartate amino transferase (AST), and alanine amino transferase (ALT). The time of death is recorded in both the CRN and BTD as obtained from the Norwegian Population Register. The last date of follow-up was July 6, 2020.

**Definition of Variables**

We used the phase III trials in newly diagnosed GBM that were published over the last 10 years as reference trials. Patients were excluded if they had WBC < 1.5 ×10⁹/L, tbc < 100 ×10⁹/L, creatinine >150 μmol/L, bilirubin >34 μmol/L or AST/ALT >3 times above the upper reference limit of the hospital laboratory at the defined time points. For disqualifying comorbidities, we used the diseases commonly listed as reasons for trial exclusion according to published phase III trials. This included patients with active heart disease (NYHA 3-4, unstable angina pectoris, myocardial infarction within last 6 months), active hepatic disease (hepatic insufficiency), or active lung disease (COPD requiring hospitalization within the last 6 months), patients with bleeding disorders, immunologic disorders with inherited or acquired immunodeficiency or iatrogenic immunosuppression other than glucocorticoid use due to GBM, recent (within the last 6 months) intracranial bleeding, recent (within the last 6 months) abscess or infection of the CNS, previous oncological disease other than nonmelanoma skin cancer and carcinoma in situ of the cervix, patients with severe psychiatric disease (eg, schizophrenia requiring recent hospitalization) and patients with developmental disorders (eg, infantile autism) or dementia. Pregnancy was also categorized as an exclusion criterion. Patients taking ≥48 mg methylprednisolone (≥16 mg TID) or ≥12 mg dexamethasone (≥4 mg TID) daily, were classified as receiving high-doses of steroids. Patients who received increasing doses of steroids up to the predefined time points for potential enrollment in a trial were also classified into a separate group. Polypharmacy was considered present if a patient was taking ≥5 drugs requiring a prescription from a physician (except for newly started drugs related to GBM).

**Ethics**

The study was approved by The Norwegian Regional Committee for Medical Research Ethics (REK 2018/2295) and the data protection offices at the CRN and OUH (PVO 2017/7084).

**Statistical Considerations**

We constructed a custom-made database using FileMaker Pro 16.0.5. Data analysis and graphic presentation were performed using GraphPad Prism 8.0.
Results

Population Characteristics

A total of 512 patients were diagnosed with GBM between 2012 and 2017, representing an incidence of 3.89 per 100,000/y. The diagnosis was made via tissue examination by a pathologist in 484 cases (94.5%), while 28 (5.5%) had their diagnosis derived from radiologic imaging only, as they were not considered candidates to undergo an invasive procedure. The median age of the entire population at diagnosis was 64 years, 133 patients (26%) were >70 years, and the median age of the patients with and without a tissue-based diagnosis was 63 and 81 years, respectively. There was a slight male predominance (1.53:1). Ten patients (2%) had disease involving both supratentorial and infratentorial regions, while 10 (2%) had solely infratentorial disease localized in the cerebellum (n = 5), brain stem (n = 3), or spinal cord (n = 2). A good performance status (ECOG ≤2) at the time of diagnosis was observed in 469 patients (91.6%). Another previous or concurrent oncological disease was the most common comorbidity (n = 75, 14.6%). Further population characteristics are outlined in Table 1 and Supplementary Figure S1.

Patterns of Care and Survival in a GBM Population

The median survival in the total population (n = 512) was 11.7 months, with 2- and 5-year survival rates of 19.3% and 7.4%, respectively (Figure 1A). The median survival times for patients with and without a tissue diagnosis were 12.3 and 2.4 months, respectively.

Among patients with a histological diagnosis (n = 484), 336 patients (69.4%) completed concurrent RT/TMZ, whereas 51 (10.5%) received RT (any dose) and started, but discontinued TMZ, 58 (12.0%) received RT only (any dose), and 36 (7.5%) received no RT or TMZ. In the group where GBM was confirmed by tissue analysis, the median survival was 14.8 months (95% CI 13.8–16.4) for patients who completed concurrent RT/TMZ, 8.0 months (6.2–10.9) for patients who received RT (any dose) and started, but discontinued TMZ, 7.6 months (5.7–9.7) for patients who received RT only (any dose), and 1.1 months (0.9–1.9) for patients who did not receive any additional oncological therapy (Figure 1B, P < .0001).

Of the patients who received TMZ in the concurrent phase, 1.5% (n = 6) developed leucopenia below the predefined threshold level of 1.5 × 10^9/L corresponding to a grade 3 toxicity or higher, 8.3% (n = 33) developed thrombocytopenia below the predefined threshold level of 100 × 10^9/L corresponding to a grade 2 toxicity or higher, and 2.3% (n = 9) elevated ALT, AST or bilirubin levels above the predefined levels corresponding to a grade 2 toxicity or higher, that required discontinuation of TMZ. Further treatment and survival characteristics are outlined in Figure 1C and Supplementary Table S2.

Proportion of Patients Found Ineligible for a Phase III Trial

Phase III trials conducted in patients with newly diagnosed GBM over the last 10 years have enrolled patients at 3 different time points; (1) before the concurrent RT/TMZ (n = 5),8,10,11,14,16 (2) midway through RT/TMZ (n = 1),9 and (3) at the end/after completion of concurrent RT/TMZ (n = 4, Figure 2A).12,13,15 Although inclusion and exclusion criteria varied between individual trials, they broadly encompassed the same set of criteria (Supplementary Table S1). Commonly, these trials recruited patients within defined age limits (18–70 y), with a supratentorial located tumor, who underwent an open biopsy or surgical resection for tissue-based diagnosis and had a good performance status (ECOG ≤2). On the other hand, they typically excluded patients with biochemical signs of hematologic, renal, or hepatic insufficiency, other predefined disqualifying comorbidities (eg, recent intracranial bleeding or infection, decompensated heart or lung disease, history of previous malignancy), disease progression before the time of randomization and patients taking increasing or high doses of steroids (Supplementary Table S1). Based on the inclusion and exclusion criteria that were used in the majority of the reference trials,7–16 we established a list of criteria a patient had to fulfill to be considered eligible for trial recruitment at 3 different time points (Figure 2B).

Using these criteria, we simulated enrollment before planned concurrent RT/TMZ by filtering by age (18–70), localization (supratentorial), undergone open biopsy or surgical resection, no disqualifying comorbidity, good performance status (ECOG ≤2), stable doses, or no glucocorticoids, and adequate hematologic, hepatic and renal function. Patients were considered ineligible if they failed one or more of these criteria. This selection excluded 290 (57%) of the patients from a potential clinical trial (Figure 3A, Supplementary Table S3). We next simulated potential enrollment midway through concurrent RT/TMZ treatment by adding the criterion that patients had to have started concurrent RT/TMZ treatment without signs of disease progression. With this scenario, 300 (59%) patients were ineligible for trial participation (Figure 3B). When we finally filtered by the criterion that patients had to have completed concurrent RT/TMZ, that is, simulating inclusion following completion of the concurrent radiochemotherapy phase, 320 (63%) of the patients were excluded (Figure 3C).
Survival Characteristics of the Potential Study Groups

We next compared the survival characteristics for eligible versus ineligible patients at different time points. Patients who potentially could have been included in a trial before the start of concurrent RT/TMZ had a median survival of 16.4 months, and the 2- and 5-year survival rates were 33.3% and 8.6%, respectively. Comparable data for the ineligible patients were 7.7 months, 14.0% and 3.0% (Figure 3D). Similar differences in survival were found at the two other time points for study inclusion (Figure 3E, F). The survival advantage for patients who fulfilled the eligibility criteria for trials at each time point was statistically significant (P < .0001, log-rank test). Compared to the group of patients who were considered ineligible for trials, the median, 2-year and 5-year survival rates were increased >2 times in the group of patients considered trial candidates (Figure 3D–F, Table 2).

Patient Characteristics of the Potential Study Groups

We further compared the characteristics of patients who were considered eligible for a trial to those considered ineligible. Before the start of concurrent RT/TMZ, compared to...
median age of 69.0 years for those found ineligible, the median age of patients who fulfilled the criteria for study enrollment was 58.0 years (P < .0001, Mann–Whitney test). Similar differences were found at both of the other time points for study enrollment (both P < .0001). In the group of patients considered eligible for trial recruitment, compared to a median ECOG of 1 among the ineligible patients, the median ECOG performance status was 0. Compared to 67% among ineligible patients, a total of 98% of patients considered trial candidates had undergone tumor resection surgery. The characteristics between the groups are outlined in Table 2.

We used data from the reference trials for external validation. Except for the survival rate, which was extracted from the control group of each trial, we utilized data from both randomized cohorts in the trials. We left out survival data from 2 trials that exclusively recruited MGMT-methylated tumors (as they have significantly better survival), and from one trial with no control group. We found that our data on patients (age, male to female ratio, ECOG status, a proportion that underwent surgical resection, median- and 2-year survival) considered to be candidates for trial recruitment corresponded well with the patients that de facto had been participants in clinical trials for GBM (Table 3).

Discussion

Our study provides a quantitative portrait of the patients who can be considered either eligible or ineligible for enrollment into phase III trials for newly diagnosed GBM. Our main result is that only a minority of the patients are eligible for inclusion into a typical RCT. Compared to a real-world GBM population, this minority formed a more homogeneous group consisting of younger patients with a better performance status that were more likely to have undergone tumor resection surgery. As these factors are associated with improved survival, it was not surprising that compared to those considered ineligible for trial participation, survival rates were markedly improved.

Our conclusion depends on; (1) that the study population represents a true real-world GBM population with patterns of care corresponding to that seen in recent population-based series, and (2) that our eligibility criteria result in the selection of a group of patients who has the characteristics of patients included in recent RCTs.

All patients within our defined geographical area with an intracranial lesion suspicious of GBM were referred to one hospital (OUH). Irrespective of how the diagnosis of GBM is made and the treatment modalities are applied, all patients are by law reported to the national CRN, where the diagnosis and further details of the disease are stored with the patient’s home address and unique national ID. The risk for missing individual patients in the current study was therefore small. We found an annual incidence of 3.89/100 000. The median age at diagnosis was 64 years, 26% of patients were over 70 years old and there was a slight male predominance. In addition, 2% presented with the infratentorial disease. These data are in accordance with
several epidemiological series over time and across different GBM populations, indicating that our population corresponds well to established nonadjustable epidemiologic features in GBM.

We further found that the diagnosis was made without tissue examination (ie, by MRI only) in 5.5% of the cases, compared to around 5–20% in previous reports. Among the patients with a tissue diagnosis, resection surgery was performed in 80%, and 2/3 completed concurrent RT/TMZ. These levels correspond to patterns of care in other population-based series (70–90% of patients undergoing resection surgery, and approximately 60% receiving first-line treatment of concurrent RT/TMZ), as do our data on overall, 2- and 5-year survival rates. Compared to a median of 0–1 in the reference trials (as several trials reported their baseline data over a range, we could not discern the true median other than over a range), the median ECOG among the patients we found eligible was 0. Lastly, depending on the different time points the median overall survival of patients we found eligible for a potential RCT ranged from 16.4–17.0 months versus 16.8 (range: 16.0–20.0) months in the reference trials. Correspondingly, the median 2-year survival ranged from 33.3–34.4% in our data versus 33.9% (30.1–40.0%) in the reference trials. Collectively, our data, therefore, indicate that the selection criteria we applied in the current study resulted in a group representative for patients typically included in a phase III trial in GBM. This
Figure 3. Simulated study group derived from a GBM population. (A) When filtering patients according to the selected study criteria, 57% of patients were considered ineligible for a clinical trial before the concurrent RT/TMZ. (B) Midway through RT/TMZ, the filtering excluded 59% of the patients, and (C) 63% of the patients were considered ineligible at the end of concurrent RT/TMZ. (D–F) Survival curves of patients found eligible compared to those found ineligible. There was a significant survival advantage ($P < .0001$) with over 2 times increased median, 2-y and 5-y survival at all time points for the patients found eligible for trials. (G) Hazard ratios of death of the patients found ineligible compared to those found eligible. RT, radiotherapy; TMZ, temozolomide.
substantiates our main conclusion that only a minority of patients with a newly diagnosed GBM is eligible for inclusion into a typical RCT.

The eligibility criteria applied in the reference trials were largely equivalent with respect to performance status, mode of diagnosis, physiological parameters, and disqualifying comorbidities. Although only 4 studies used 70 years as an upper age limit, enrolled patients tended to be younger also in the investigation where no such restriction was imposed. In line with the Stupp trial, we chose to use 70 years as an upper limit for potential trial inclusion. Still, we ended up with 58.0 years as the median age for trial eligible patients, compared to median age of the randomized patients ranging from 54.0 to 59.0 in the reference trials. As the median age at diagnosis in our unselected population was 64 years, we suspect that there has been a tendency to exclude older patients even in the studies where the age limit was not applied.

Phase III clinical trials are fundamental for establishing standards of care. Our data, where approximately 60% of patients are excluded from trials, suggest that current trial protocols only provide treatment guidance to a minority of the patients. As the generalizability of trial results is restricted to the population that has been studied, it remains uncertain how the majority should be treated. Unfortunately, the patients with the worst prognosis, where new treatment options are needed the most, are represented in this group.

It is well known that patients in clinical trials may be selected to such an extent that study results do not directly apply to the real-world situation. In brain tumors, skewed inclusion was described for anaplastic glioma by Macdonald and Cairncross’ group over 3 decades ago. Later studies evaluating survival of glioma patients described significant survival advantage of those considered eligible for experimental trials. As the median age at diagnosis in our unselected population was 64 years, we suspect that there has been a tendency to exclude older patients even in the studies where the age limit was not applied.

Phase III clinical trials are fundamental for establishing standards of care. Our data, where approximately 60% of patients are excluded from trials, suggest that current trial protocols only provide treatment guidance to a minority of the patients. As the generalizability of trial results is restricted to the population that has been studied, it remains uncertain how the majority should be treated. Unfortunately, the patients with the worst prognosis, where new treatment options are needed the most, are represented in this group.

It is well known that patients in clinical trials may be selected to such an extent that study results do not directly apply to the real-world situation. In brain tumors, skewed inclusion was described for anaplastic glioma by Macdonald and Cairncross’ group over 3 decades ago. Later studies evaluating survival of glioma patients described significant survival advantage of those considered eligible for experimental trials. As the median age at diagnosis in our unselected population was 64 years, we suspect that there has been a tendency to exclude older patients even in the studies where the age limit was not applied.
The major strengths of this study lie in the unique surveillance of GBM within a well-defined geographical area enabled by the CRN and BTD, as well as in the number of patients, the individual-level data, and that the results were derived from a real-world population setting. Moreover, the data were restricted to one health center only (OUH), thereby reducing the possible confounding effect of differences in access to health care services between health centers.

The major limitation of the study is the retrospective sampling of some of the data from individual patient records. As this introduces a degree of subjectivity primarily affecting scoring of ECOG status and patient comorbidity, 2 independent researchers went through the data of each patient. The retrospective design, moreover, cannot discern certain variables that might affect trial eligibility, such as logistical issues as well as attitudes and willingness to participate in a trial, that further exclude patients from RCTs.\(^7\)\(^-\)\(^16\),\(^38\) A further limitation is the lack of molecular data, especially IDH- and MGMT methylation status. This aspect is important as the stratification of patients according to molecular data will be important in future trials.

Concerns have been raised with regard to the low accrual rate of patients into neuro-oncological trials, which is estimated to be only approximately 10\%.\(^44\) Barriers for trial accrual are related both to physicians (eg, awareness), and organizations/institutions (eg, infrastructure, economy).\(^46\) In addition, adjustments of eligibility criteria for trials to increase enrollment have gained increasing attention in the academic community in recent years.\(^46\),\(^47\) In this study, most patients were excluded based on age and comorbidities. With an increasingly aging population, it is expected that the number of patients with GBM will increase.\(^5\) To enroll more patients in trial accepting a wider age span, as well as allowing patients with a history of the malignant disease whose natural history or treatment does not have the potential to interfere with trial endpoints, may therefore be the two most useful criteria to increase the fraction of eligible patients.

In summary, we have provided a quantitative portrait of the selection bias of GBM patients in phase III clinical trials. We have shown that only a minority of patients in a real-world GBM population can be expected to fulfill standard eligibility in such trials and that these patients are younger, have better performance status and fewer comorbidities, and are more likely to have undergone tumor resection. Consequently, cohorts included in RCTs have improved survival compared to an unselected real-world population. This selection bias should be taken into consideration when trial results are used to guide treatment.

**Keywords**

clinical trials | eligibility | glioblastoma | selection bias | survival.
5. Korja M, Raj R, Soppä K, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. *Neuro Oncol.* 2018;21(3):370–379.

6. Rothwell PM. External validity of randomised controlled trials: “To whom do the results of this trial apply?” *The Lancet.* 2005;365(9453):82–93.

7. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. *J Clin Oncol.* 2013;31(32):4085–4091.

8. Stupp R, Hegi ME, Gorlia T, et al. Concomitant temozolomide and radiotherapy for the treatment of glioblastoma. *N Engl J Med.* 2005;352(15):1997–2006.

9. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of temozolomide for newly diagnosed glioblastoma. *N Engl J Med.* 2019;380(15):1452–1463.

10. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy for glioblastoma. *Lancet.* 2015;385(9982):3121–3131.

11. Voloshina N, van den Bent MJ, et al. Cilengitide combined with standard of care chemotherapy for patients with newly diagnosed glioblastoma. *Lancet Oncol.* 2017;18(10):1373–1385.

12. Gilbert MR, Dignam JJ, Armstrong TS, et al. Bevacizumab plus radiotherapy for glioblastoma. *Neuro Oncol.* 2019;21(1):47–58.

13. Adams H, Chiachana KL, Avendaño J, Liu B, Raza SM, Quiñones-Hinojosa A. Adult cerebellar glioblastoma: understanding survival and prognostic factors using a population-based database from 1973 to 2013. *World Neurosurg.* 2013;80(6):e237–e243.

14. Cho HJ, Zhao J, Jung SW, et al. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. *Neuro Oncol.* 2019;21(1):1–12.

15. Helseth R, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. *JAMA Oncol.* 2016;2(11):1460–1469.

16. Heikkilä P, Harju L, Kallioniemi M, et al. Glioma outcomes registry in Finland: a population-based study of 1012 patients with glioblastoma. *Neuro Oncol.* 2014;16(7):798–806.

17. Hovestadt V, Grossman SA, et al. Association of patterns of performance status: an empirical analysis. *J Neuro-Oncol.* 2014;122(14):2206–2215.

18. Kallioniemi M, Raj R, Seppä K, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. *Neuro Oncol.* 2018;21(3):370–379.

19. Korja M, Raj R, Soppä K, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. *Neuro Oncol.* 2018;21(3):370–379.

20. Korja M, Raj R, Seppä K, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. *Neuro Oncol.* 2018;21(3):370–379.

21. Korja M, Raj R, Seppä K, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. *Neuro Oncol.* 2018;21(3):370–379.

22. Skaga et al. Real-world validity of randomized controlled phase III trials

Neuro-Oncology Advances

11

Downloaded from https://academic.oup.com/noa/article/3/1/vdab008/6152004 by guest on 10 July 2021
42. Perry JR, DeAngelis LM, Schold SC Jr, et al. Challenges in the design and conduct of phase III brain tumor therapy trials. *Neurology*. 1997;49(4):912–917.

43. Chang SM, Reynolds SL, Butowski N, et al. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. *Neuro Oncol*. 2005;7(4):425–434.

44. Vanderbeek AM, Rahman R, Feil G, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? *Neuro Oncol*. 2018;20(8):1034–1043.

45. Lee EQ, Chukwueke UN, Hervey-Jumper SL, et al. Barriers to accrual and enrollment in brain tumor trials. *Neuro Oncol*. 2019;21(5):536–518.

46. Kim ES, Bruinooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: american society of clinical oncology and friends of cancer research joint research statement. *J Clin Oncol*. 2017;35(33):3737–3744.

47. Lee EQ, Weiler M, Sul J, et al. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. *Neuro Oncol*. 2020;22(5):601–612.